On March 20, 2026, Apimeds Pharmaceuticals US, Inc. rejected a stockholder consent to remove its board members and executives, claiming it violated Delaware law and contractual agreements, making it null and void. The company affirmed that its leadership remains unchanged, and it continues to pursue its merger with MindWave Innovations Inc.